A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...

A new blood test may make it easier to detect the most dangerous forms of prostate cancer early. In a study from Karolinska ...

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...

Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer ...

Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.

Before joints become painful, psoriatic arthritis (PsA) often begins silently as enthesitis—inflammation where tendons and ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

After a group of Democratic lawmakers shared a video urging the military and intelligence communities to defy any illegal orders from the president, Trump called them "traitors" who should be "put on ...